To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.
General Information
DRAVP ID DRAVPe02151
Peptide Name N/A
Sequence SGINASVVNIQKEIDRLNEVAKNLNESLIDLQEL
Sequence Length 34
UniProt ID P0DTC2
Taxon ID 2697049
Source HR segment of SARS-CoV
Validation Experimentally Validated
Origin Information
Gene Name/ID S2(43740568)
GenBank QHD43416.1
Amino Acid position 1170-1203
Domain Accession ID Not Available
Nucleotide sequence ID MN908947.3
Molecular Type Genomic RNA
Chromosomal Position Chromosome:21,563 - 25,384
Activity Information
Target Organism SARS-CoV-2
Assay antiviral Assay
Activity Not Avaialble
Hemolytic Activity No hemolysis information or data found in the reference(s) presented in this entry
Cytotoxicity No cytotoxicity information found in the reference(s) presented
Binding Target Glycoprotein. Gp41
Mechanism ting the virus’ action before adsorption, at a percentage above
Structure Information
Predicted Structure Download No predicted structure available
Linear/Cyclic Cyclic
N-terminal Modification N-terminal leucine/isoleucine zipper-like sequence
C-terminal Modification C-terminal heptad repeat located upstream
Other Modification None
Stereochemistry L
Physicochemical Information
Formula C162H276N46O57
Absent amino acids RDCHMPWOU
Common amino acids NL
Mass 3780.25
Pl 4.36
Basic residues 3
Acidic residues 6
Hydrophobic residues 18
Net charge -3
Boman Index 0.9
Hydrophobicity -0.218
Aliphatic Index 134.71
Half Life
Extinction Coefficient cystines 0
Absorbance 280nm 0
Polar residues 22
Literature Information
Literature 1
Title Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy
Pubmed ID 14499001
Reference BMC microbiology, 3, 20.
Author Kliger, Y., & Levanon, E. Y. (2003).
To the extent possible under law, the person who associated CC0 with this work has waived all copyright and related or neighboring rights to this work.